Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Entera Bio is a cash-burning, single-pipeline biotech (EB613) with quality at 1.6/10 and repeated earnings misses; price momentum is positive, but no reliable analyst target exists and little upside is left to the technical target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline is concentrated in EB613, flagged as a HIGH concentration risk, in a binary industry (biotechnology). Bear case | EB613 advances through development milestones without a negative setback over 12 months. | ↓Deteriorating |
| CounterConcentration in one asset can be a strength if EB613 succeeds, since the stock would then carry outsized upside. | ||
Entera Bio is cash-burning with negative free cash flow, no competitive moat and quality at 1.6/10, well below the 4.0 floor. Quality breakdown | Cash burn narrows or funding is secured so that quality improves above 4.0 over the next 12 months. | →Stable |
| CounterPre-revenue biotechs are expected to burn cash, and quality metrics such as margins are structurally zero until a product is approved, so the low score may overstate distress. | ||
Recent quarterly results show 2 misses (EPS -0.11 vs -0.07 estimated, then -0.14 vs -0.08), with average surprise of -22.7%. Earnings | Quarterly losses narrow to or below estimates over the next 12 months. | →Stable |
| CounterWith estimates near -0.07 per share, small absolute differences create large percentage misses, so the percent surprise exaggerates the miss. | ||
Momentum scores 6.1/10 with rising OBV and the price above its 200-day average, with a golden cross and bullish MACD. Momentum breakdown | The price holds above its 200-day average over the next 12 months. | ↑Improving |
| CounterVolume component is scored 0.0 and the stock sits only 2.5% below the 3.22 technical target, so the breakout could stall quickly on thin volume. | ||
The raw analyst target of $9.75 was rejected as implausible against a $3.14 price (3.1x), so no reliable analyst upside exists and the technical target is only 3.22. Bear case | A credible analyst target appears or a clinical catalyst revalues the shares above the 3.22 technical target. | ↓Deteriorating |
| CounterThe rejected target reflects analysts valuing the pipeline above the current price, so the market may be significantly undervaluing the pipeline. | ||
CounterConcentration in one asset can be a strength if EB613 succeeds, since the stock would then carry outsized upside.
CounterPre-revenue biotechs are expected to burn cash, and quality metrics such as margins are structurally zero until a product is approved, so the low score may overstate distress.
CounterWith estimates near -0.07 per share, small absolute differences create large percentage misses, so the percent surprise exaggerates the miss.
CounterVolume component is scored 0.0 and the stock sits only 2.5% below the 3.22 technical target, so the breakout could stall quickly on thin volume.
CounterThe rejected target reflects analysts valuing the pipeline above the current price, so the market may be significantly undervaluing the pipeline.
| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 6.6 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 9.7 |
| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 6.1 |
| growth rank | 5.0 |
| Component | Sub-score |
|---|---|
| bollinger | 1.2 |
| support resistance | 2.7 |
| 52w position | 5.7 |
| Component | Sub-score |
|---|---|
| short interest | 8.0 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 5.2 |
| debt equity | 10.0 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
Quality below minimum threshold.
L1:HARD_BLOCK:QUALITY_FLOORnone
SetupBreakout — Golden cross, above all MAs, RSI 60, MACD bullish
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 10.05.
The strongest dimensions are Value at 9.0, Momentum at 8.1, and Sentiment at 7.5; the weakest are Quality at 1.6, Catalyst at 2.8, and Technical at 3.2. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 10.05 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifQuality score stays below 2.0 from the current 1.6 for 2 consecutive quarters.
Trip ifEB613 share of pipeline stays above 80% with no second clinical asset.
Trip ifEPS surprise stays below -25% for 2 consecutive quarters.
Trip ifPrice falls below the 2.92 stop-loss level.
Trip ifPrice falls below 2.50 from the current 3.14.